BioCentury | Apr 7, 2017
Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
BC Week In Review | Mar 15, 2017
Financial News

Aequus Pharmaceuticals completes follow-on

Neurology, ophthalmic and transplant company Aequus Pharmaceuticals Inc. (TSX-V:AQS; OTCQB:AQSZF) raised C$5.2 million ($3.8 million) through the sale of 17.3 million units at C$0.30 in a bought deal underwritten by Canaccord Genuity on March 13....
BC Week In Review | Jan 18, 2017
Clinical News

AQS1301: Clinical trial started

Aequus began a Canadian proof-of-concept (POC) trial to evaluate once-weekly transdermal AQS1301 for 4 weeks in 8 healthy male volunteers. Aequus and Corium are partnered to develop AQS1301. Aequus has an exclusive, worldwide license to...
BC Week In Review | Sep 19, 2016
Company News

Duchesnay, Alliance Pharma deal

The partners added Germany, France, Italy and six additional undisclosed EU countries to a 2015 deal granting Alliance rights to market Diclectin doxylamine/pyridoxine in the U.K. Alliance said it will pay L1 million ($1.3 million)...
BC Week In Review | Sep 19, 2016
Financial News

Aequus Pharmaceuticals completes private placement

Aequus Pharmaceuticals Inc. (TSX-V:AQS; OTCQB:AQSZF), Vancouver, B.C.   Business: Drug delivery, Neurology, Gastrointestinal   Date completed: 2016-09-13   Type: Private placement   Raised: C$2.7 million ($2.1 million)   Shares: 9.1 million   Price: C$0.30  ...
BC Week In Review | Sep 12, 2016
Financial News

Aequus Pharmaceuticals proposes private placement

Aequus Pharmaceuticals Inc. (TSX-V:AQS; OTCQB:AQSZF), Vancouver, B.C.   Business: Drug delivery, Neurology, Gastrointestinal   Date announced: 2016-09-06   Type: Private placement   To be raised: Up to C$4 million ($3.1 million)   Shares: 13.3 million...
BC Week In Review | Feb 22, 2016
Clinical News

AQS1301: Phase I data

A double-blind, placebo-controlled, Canadian Phase I trial in 12 healthy volunteers showed that once-weekly transdermal AQS1301 was well tolerated with no serious adverse events reported. Aequus and Corium are partnered to develop AQS1301. Aequus has...
BC Week In Review | Jan 18, 2016
Financial News

Aequus Pharmaceuticals completes private placement

Aequus Pharmaceuticals Inc. (TSX-V:AQS; OTCQB:AQSZF), Vancouver, B.C.   Business: Neurology, Drug delivery   Date completed: 2016-01-13   Type: Private placement   Raised: C$2.6 million ($1.9 million)   Shares: 5.3 million   Price: C$0.50   Shares...
BC Week In Review | Nov 9, 2015
Financial News

Aequus Pharmaceuticals completes private placement

Aequus Pharmaceuticals Inc. (TSX-V:AQS; OTCQB:AQSZF), Vancouver, B.C.   Business: Neurology, Drug delivery   Date completed: 2015-10-30   Type: Private placement   Raised: C$1.2 million ($944,336)   Shares: 2.5 million   Price: C$0.50   Shares after...
BC Week In Review | Oct 12, 2015
Financial News

Aequus Pharmaceuticals proposes private placement

Aequus Pharmaceuticals Inc. (TSX-V:AQS; OTCQB:AQSZF), Vancouver, B.C.   Business: Neurology, Drug delivery   Date announced: 2015-10-05   Type: Private placement   To be raised: TBD   Shares: TBD   Price prior: C$0.62   Shares outstanding...
Items per page:
1 - 10 of 20